United States Post-Marketing Observational Cardiovascular Safety Study in Patients taking Naloxegol (Naloxegol US Post-Market Requirement CV Safety) First published 16/03/2017 Last updated 14/03/2024 EU PAS number:EUPAS18201 Study Ongoing